share_log

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga ·  Mar 7, 2023 21:10

Gainers

  • Virax Biolabs Group (NASDAQ:VRAX) shares increased by 129.3% to $1.52 during Tuesday's pre-market session. The company's market cap stands at $19.4 million.
  • Adial Pharmaceuticals (NASDAQ:ADIL) shares moved upwards by 54.76% to $0.65. The company's market cap stands at $18.5 million.
  • Novo Integrated Sciences (NASDAQ:NVOS) stock rose 29.25% to $0.22. The market value of their outstanding shares is at $13.4 million.
  • Tenax Therapeutics (NASDAQ:TENX) stock moved upwards by 19.02% to $0.78. The market value of their outstanding shares is at $7.2 million.
  • F-star Therapeutics (NASDAQ:FSTX) shares increased by 14.91% to $7.01. The market value of their outstanding shares is at $154.0 million.
  • Unicycive Therapeutics (NASDAQ:UNCY) shares rose 10.48% to $1.37. The market value of their outstanding shares is at $20.6 million.

Losers

  • Cara Therapeutics (NASDAQ:CARA) shares declined by 25.1% to $7.5 during Tuesday's pre-market session. The company's market cap stands at $403.0 million. As per the press release, Q4 earnings came out yesterday.
  • Xtant Medical Holdings (AMEX:XTNT) stock decreased by 16.3% to $0.77. The market value of their outstanding shares is at $83.6 million. As per the press release, Q4 earnings came out today.
  • Ambrx Biopharma (NYSE:AMAM) stock declined by 10.85% to $11.18. The market value of their outstanding shares is at $431.7 million.
  • Orchestra BioMed Hldgs (NASDAQ:OBIO) shares decreased by 10.24% to $16.32. The market value of their outstanding shares is at $515.9 million.
  • Marker Therapeutics (NASDAQ:MRKR) stock declined by 8.72% to $1.94. The company's market cap stands at $16.5 million.
  • Zynex (NASDAQ:ZYXI) stock decreased by 7.35% to $11.5. The market value of their outstanding shares is at $442.6 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment